Northeast Georgia Health System launches emergency care wait time tracker for 16 locations
Now, the Northeast Georgia Health System is launching an emergency care online tracker so those in need can see, in real-time, how long they'll have to wait at 16 locations for emergency and urgent medical care.
The health system said the tracking system will cover the wait times for emergency rooms at Northeast Georgia Medical Center Gainesville, and the NGMC Braselton, Barrow, Habersham and Lumpkin facilities.
[DOWNLOAD: Free WSB-TV News app for alerts as news breaks]
'The emergency room wait times indicate how long you can expect to wait from the moment you arrive until you are seen by a qualified medical professional,' Walter Wiley, executive director for Emergency, Trauma, Observation and EMS Services at NGHS, said in a statement. 'Once you've been assessed, any additional wait time will be determined based on the severity of your situation compared to others who are waiting for care.'
TRENDING STORIES:
Ex-GA sheriff lieutenant pleads guilty to pocketing funds from citation payments
Decatur announces start of $8.5 million City Square transformation project
73-year-old GA woman wanted for identity fraud
The wait time tracker will also cover the five emergency rooms and 11 urgent care locations in Bethlehem, Braselton, Buford, Cleveland, Dacula, Dahlonega, Dawsonville, Gainesville, Jefferson, Oakwood and Toccoa.
NGHS said urgent care clinics are good for non-life-threatening conditions that still need quick treatment like colds, flus, bronchitis and other conditions.
'Providing wait times online allows patients to make the best decision for their situation, whether that means heading to one of our five hospitals or seeking urgent care instead.' Wiley added. 'We're also sharing information about when you should head to the emergency room or call 9-1-1, and when you should head to urgent care or sign up for a video visit.'
To check wait times for the different facilities, head online here for emergency rooms and here for urgent care.
[SIGN UP: WSB-TV Daily Headlines Newsletter]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
3 days ago
- Associated Press
SpeciCare Introduces Cancer Drug Sensitivity Testing to Identify the Most Effective Treatment for Cancer Patients
Discover Which Cancer Treatment Works the Best on Every Individual Cancer by Testing Live Tissue Against Over 300 FDA Approved Medications 'Too often, cancer patients are placed on therapies that offer little benefit but come with devastating side effects'— Dr. Ken Dixon GAINESVILLE, GA, UNITED STATES, August 8, 2025 / / -- SpeciCare is proud to announce the nationwide availability of its Cancer Drug Sensitivity Testing ( CDST ) service—an innovative advancement in precision medicine that empowers oncologists and patients to identify the most effective therapy for each individual's unique cancer, without trial and error, unnecessary side effects, or invasive procedures. Using advanced laboratory analysis, CDST evaluates a live cancer specimen against a library of around 300 unique FDA-approved cancer drugs and emerging compounds. This real-time drug sensitivity data provides oncologists with a personalized treatment roadmap that highlights which drugs are most likely to be effective—and which are not—before treatment begins. 'Too often, cancer patients are placed on therapies that offer little benefit but come with devastating side effects,' said Dr. Ken Dixon, Chief Medical Officer at SpeciCare. 'Drug sensitivity testing is changing that. It gives us a chance to get it right the first time.' A Major Step Forward in Personalized Oncology Developed in a leading U.S. research university, this cutting-edge technology is now available through SpeciCare's national precision medicine platform. It offers a safer, faster, and more personalized way to treat cancer—especially for patients with aggressive or difficult-to-treat tumors. Key benefits include: No additional procedures beyond the standard surgical or biopsy tissue collection Precise drug response data to guide treatment decisions Fewer unnecessary side effects and less guesswork Faster path to effective treatment Cryopreservation: Keeping Options Open for the Future If sufficient tissue remains after CDST is completed, SpeciCare offers optional cryopreservation of the cancer biospecimen. This ensures the sample is preserved in a living state for future testing, including genomic sequencing, immunotherapy matching, or enrollment in future clinical trials. 'Every tumor is different, and cancer is constantly evolving,' said Dr. Dixon. 'Cryopreservation gives patients ongoing control over their cancer journey, even as science continues to advance.' A Call to Oncologists and Cancer Care Providers SpeciCare invites oncologists, surgical centers, and cancer care providers to integrate CDST into their patient care protocols. The service is simple to implement and supported by the SpeciCare clinical team every step of the way—from tissue collection coordination to detailed result interpretation. About SpeciCare Located in Gainesville, Georgia, SpeciCare is a leader in personalized cancer care, specializing in live tissue preservation, clinical trial matching, and advanced diagnostic services. SpeciCare's mission is to put control back in the hands of patients and their doctors by preserving and utilizing live tumor tissue to unlock powerful insights for treatment. Scott Ford Emerge Marketing, LLC +1 417-230-7082 email us here Visit us on social media: LinkedIn Facebook Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
4 days ago
- Yahoo
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership
CorMedix to pay Melinta $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders The agreement also includes a regulatory milestone payment of up to $25 million and royalties Transformational deal that strengthens and diversifies commercial product portfolio for CorMedix PARSIPPANY, N.J., August 07, 2025--(BUSINESS WIRE)--Melinta Therapeutics, LLC ("Melinta"), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announces that it has entered into a definitive agreement to be acquired by CorMedix Inc. ("CorMedix") (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The acquisition is a testament to the exceptional value Melinta has created through its strong portfolio, culture, capabilities, and experienced team within the hospital ecosystem for acute care. "This acquisition represents a milestone achievement for Melinta and validates our position as a recognized leader in acute care," said Christine Ann Miller, CEO of Melinta Therapeutics. "I'm incredibly proud of our accomplishments. Through our talented team's dedication, we have undergone an extraordinary transformation to build a highly sought-after commercialization platform with sustainable growth and profitability. By joining forces with CorMedix, we're creating a stronger organization that will accelerate both our mission to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision that all patients who need our therapies receive them." Since becoming privately owned by affiliates of healthcare investment firm Deerfield Management Company, L.P. in 2020, Melinta has demonstrated exceptional organizational evolution across operations, culture, and strategic positioning to achieve 85% revenue growth, positive cash flow, and sustainable profitability, while increasing employee satisfaction and building a highly talented team. Melinta has strengthened its position with global presence through ex-US partnerships and seven business development deals, including strategic partnership with BARDA to advance two FDA-approved antibiotics for use in pediatric patients, as well as the development of one product for use against biothreat pathogens.i This comprehensive evolution has established Melinta as a preferred partner who is fully integrated within the hospital ecosystem. This acquisition will expand CorMedix's commercial portfolio with six marketed, highly differentiated, hospital- and clinic-focused infectious disease products, including REZZAYO® (rezafungin for injection), MINOCIN® (minocycline) for Injection, VABOMERE® (meropenem and vaborbactam), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin), BAXDELA® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL® (metoprolol succinate)ii. The portfolio's flagship product, REZZAYO® is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation (BMT), which is expected to be completed in 1H2026. The addition of Melinta's high-performing team, innovative assets, and a pipeline expansion indication positions CorMedix to deliver on its ambition of becoming a leader in the specialty pharmaceutical business. "The combination of CorMedix and Melinta represents a compelling opportunity to create a specialty pharmaceutical leader with enhanced capabilities to serve patients," said Joseph Todisco, Chief Executive Officer of CorMedix Inc. "Melinta's proven commercial platform and portfolio perfectly complement our own, and once combined we will have the scale, resources, and expertise to accelerate innovation while creating significant value for our stakeholders. We are thrilled to welcome the talented Melinta team and look forward to building on our shared commitment to excellence in this space." "Under Christine's leadership, the transformation of Melinta has been remarkable," said Jonathan Leff, Board Member of Melinta and Partner at Deerfield Management Company. "Through focused execution and strategic investment in its commercial capabilities, the Melinta team has built a high-performing organization that has consistently exceeded expectations. The combination with CorMedix reflects the strategic value of Melinta's infrastructure and positions the combined company for continued growth under Joe's leadership. We look forward to this next chapter." Under the terms of the agreement, which has been approved by the CorMedix and Melinta Board of Directors respectively, CorMedix will pay Melinta $300 million in upfront consideration (subject to customary adjustments), comprised of $260 million in cash and $40 million in CorMedix equity (in the form of pre-funded warrants) issued to Melinta shareholders. The agreement also contains an additional regulatory milestone of up to $25 million (payable in cash or shares at CorMedix's election) for the FDA approval of REZZAYO® for prophylaxis of invasive fungal infections in adults undergoing allogenic BMT, if the milestone event is achieved by June 30, 2029. Furthermore, the agreement includes tiered royalties on REZZAYO U.S. net sales and low-single-digit royalties on MINOCIN® for injection U.S. net sales. The merger is subject to customary closing conditions and U.S. regulatory approval and is expected to close in September. Advisors Evercore is acting as exclusive financial advisor and Fenwick & West LLP is acting as legal advisor to Melinta. Katten Muchin Rosenman LLP is acting as legal advisors for Deerfield Management Company, L.P. About Melinta Therapeutics Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that's how we make the most meaningful impact. At Melinta, we're visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), MINOCIN® (minocycline) for Injection, ORBACTIV® (oritavancin), REZZAYO® (rezafungin for injection), TOPROL-XL® (metoprolol succinate) and VABOMERE® (meropenem and vaborbactam). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, including their important safety information, visit About REZZAYO® (rezafungin for injection) REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data. REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. IMPORTANT SAFETY INFORMATIONREZZAYO is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins. REZZAYO may cause infusion-related reactions, including flushing, sensation of warmth, urticaria, nausea, or chest tightness. If these reactions occur, slow or pause the infusion. REZZAYO may cause photosensitivity. Advise patients to use protection from sun exposure and other sources of UV radiation. Abnormalities in liver tests have been seen in clinical trial patients treated with REZZAYO. Monitor patients who develop abnormal liver tests and evaluate patients for their risk/benefit of continuing REZZAYO therapy. Most common adverse reactions (incidence 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia. Please see the full Prescribing Information for REZZAYO (rezafungin for injection), available at ______________________ i These projects have been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00022. ii TOPROL-XL® is a registered trademark of the AstraZeneca group of companies. View source version on Contacts Susan Blum, CFOsblum@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 days ago
- Business Wire
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership
PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC ('Melinta'), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announces that it has entered into a definitive agreement to be acquired by CorMedix Inc. ('CorMedix') (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The acquisition is a testament to the exceptional value Melinta has created through its strong portfolio, culture, capabilities, and experienced team within the hospital ecosystem for acute care. 'This acquisition represents a milestone achievement for Melinta and validates our position as a recognized leader in acute care,' said Christine Ann Miller, CEO of Melinta Therapeutics. 'I'm incredibly proud of our accomplishments. Through our talented team's dedication, we have undergone an extraordinary transformation to build a highly sought-after commercialization platform with sustainable growth and profitability. By joining forces with CorMedix, we're creating a stronger organization that will accelerate both our mission to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision that all patients who need our therapies receive them.' Since becoming privately owned by affiliates of healthcare investment firm Deerfield Management Company, L.P. in 2020, Melinta has demonstrated exceptional organizational evolution across operations, culture, and strategic positioning to achieve 85% revenue growth, positive cash flow, and sustainable profitability, while increasing employee satisfaction and building a highly talented team. Melinta has strengthened its position with global presence through ex-US partnerships and seven business development deals, including strategic partnership with BARDA to advance two FDA-approved antibiotics for use in pediatric patients, as well as the development of one product for use against biothreat pathogens. i This comprehensive evolution has established Melinta as a preferred partner who is fully integrated within the hospital ecosystem. This acquisition will expand CorMedix's commercial portfolio with six marketed, highly differentiated, hospital- and clinic-focused infectious disease products, including REZZAYO ® (rezafungin for injection), MINOCIN ® (minocycline) for Injection, VABOMERE ® (meropenem and vaborbactam), KIMYRSA ® (oritavancin), ORBACTIV ® (oritavancin), BAXDELA ® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL ® (metoprolol succinate) ii. The portfolio's flagship product, REZZAYO ® is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation (BMT), which is expected to be completed in 1H2026. The addition of Melinta's high-performing team, innovative assets, and a pipeline expansion indication positions CorMedix to deliver on its ambition of becoming a leader in the specialty pharmaceutical business. 'The combination of CorMedix and Melinta represents a compelling opportunity to create a specialty pharmaceutical leader with enhanced capabilities to serve patients,' said Joseph Todisco, Chief Executive Officer of CorMedix Inc. 'Melinta's proven commercial platform and portfolio perfectly complement our own, and once combined we will have the scale, resources, and expertise to accelerate innovation while creating significant value for our stakeholders. We are thrilled to welcome the talented Melinta team and look forward to building on our shared commitment to excellence in this space.' 'Under Christine's leadership, the transformation of Melinta has been remarkable,' said Jonathan Leff, Board Member of Melinta and Partner at Deerfield Management Company. 'Through focused execution and strategic investment in its commercial capabilities, the Melinta team has built a high-performing organization that has consistently exceeded expectations. The combination with CorMedix reflects the strategic value of Melinta's infrastructure and positions the combined company for continued growth under Joe's leadership. We look forward to this next chapter.' Under the terms of the agreement, which has been approved by the CorMedix and Melinta Board of Directors respectively, CorMedix will pay Melinta $300 million in upfront consideration (subject to customary adjustments), comprised of $260 million in cash and $40 million in CorMedix equity (in the form of pre-funded warrants) issued to Melinta shareholders. The agreement also contains an additional regulatory milestone of up to $25 million (payable in cash or shares at CorMedix's election) for the FDA approval of REZZAYO ® for prophylaxis of invasive fungal infections in adults undergoing allogenic BMT, if the milestone event is achieved by June 30, 2029. Furthermore, the agreement includes tiered royalties on REZZAYO U.S. net sales and low-single-digit royalties on MINOCIN ® for injection U.S. net sales. The merger is subject to customary closing conditions and U.S. regulatory approval and is expected to close in September. Advisors Evercore is acting as exclusive financial advisor and Fenwick & West LLP is acting as legal advisor to Melinta. Katten Muchin Rosenman LLP is acting as legal advisors for Deerfield Management Company, L.P. About Melinta Therapeutics Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that's how we make the most meaningful impact. At Melinta, we're visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), MINOCIN ® (minocycline) for Injection, ORBACTIV ® (oritavancin), REZZAYO ® (rezafungin for injection), TOPROL-XL ® (metoprolol succinate) and VABOMERE ® (meropenem and vaborbactam). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, including their important safety information, visit About REZZAYO ® (rezafungin for injection) REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data. REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. IMPORTANT SAFETY INFORMATION REZZAYO is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins. REZZAYO may cause infusion-related reactions, including flushing, sensation of warmth, urticaria, nausea, or chest tightness. If these reactions occur, slow or pause the infusion. REZZAYO may cause photosensitivity. Advise patients to use protection from sun exposure and other sources of UV radiation. Abnormalities in liver tests have been seen in clinical trial patients treated with REZZAYO. Monitor patients who develop abnormal liver tests and evaluate patients for their risk/benefit of continuing REZZAYO therapy. Most common adverse reactions (incidence 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia. Please see the full Prescribing Information for REZZAYO (rezafungin for injection), available at
